Overview
ICB Pharma is an international research company operating in human and animal health, crop protection, and pest management. Its research focuses on nano- and micro-encapsulation and the development of products for these fields.
Financials
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2000-09-11. Active
58 1090 2008 0000 0001 5878 6983- 86 1090 2008 0000 0001 5878 6964
- 95 1090 2008 0000 0001 5878 6996
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Real estate
| Type | Amount |
|---|---|
Land (incl. perpetual usufruct) | $570.3K$570,316 |
Buildings and premises | $3.3M$3,332,496 |
Public aid
30 public aid cases recorded, with a total value of $665,370.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 19, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $226$226 | Fundusz Górnośląski S.A. | |
| Feb 3, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $226$226 | Fundusz Górnośląski S.A. | |
| Jan 16, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $31,399$31,399 | Fundusz Górnośląski S.A. |
Tenders
No recorded participation in tenders.
Trademarks
ICB Pharma holds 27 active trademarks registered with the Polish Patent Office. 1 application is pending. The first mark was filed in 2002.
| Mark | Protected until | |
|---|---|---|
| SILICU(word) | Oct 16, 2034 | |
| triabor(word) | Oct 16, 2034 | |
| CALPRONE(word) | Mar 13, 2034 | |
| TRIACYNK(word) | Mar 13, 2034 | |
| DIFUNGOFF(word) | Aug 28, 2033 |
Authorized Representatives
Manner of representation
In the case of a one-person management board, the company is represented by a member of the management board acting independently. If the management board is multi-member, the company is represented by two members of the management board acting jointly, or one member of the management board acting jointly with a commercial proxy.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Paweł Świętosławski (49) | 10,000 | $135,062.13 | 50% |
Tomasz Świętosławski (52) | 10,000 | $135,062.13 | 50% |
Paweł Świętosławski and Tomasz Świętosławski hold a combined 100% – the ownership structure indicates family control.
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Grupa IncoS.A. | $126,224,896.67 | inco.pl |
FAQ
Last updated: 2026-03-24